V. Leussink

发表

High-dose methylprednisolone therapy in multiple sclerosis induces apoptosis in peripheral blood leukocytes.

U. Merschdorf, R. Gold, K. Toyka, 2001, Archives of neurology.

Long-term B-lymphocyte depletion with rituximab in patients with relapsing-remitting multiple sclerosis.

H. Hartung, B. Hemmer, B. Kieseier, 2009, Archives of neurology.

[Aspects of nutrition for prevention and treatment of chronic neurological diseases].

V. Leussink, 2019, Der Nervenarzt.

Rituximab induces clinical stabilization in a patient with fulminant multiple sclerosis not responding to natalizumab

H. Hartung, B. Kieseier, G. Meyer zu Hörste, 2008, Journal of Neurology.

Subcutaneous immunoglobulins in the treatment of chronic immune-mediated neuropathies

H. Hartung, B. Kieseier, M. Stettner, 2016, Therapeutic advances in neurological disorders.

Fampridine‐PR (prolonged released 4‐aminopyridine) is not effective in patients with inflammatory demyelination of the peripheral nervous system

H. Hartung, C. Warnke, M. Stettner, 2016, Journal of the peripheral nervous system : JPNS.

Risks and benefits of multiple sclerosis therapies: need for continual assessment?

H. Hartung, H. Wiendl, B. Kieseier, 2011, Current opinion in neurology.

Type III systemic allergic reaction to natalizumab.

H. Hartung, R. Gold, B. Kieseier, 2008, Archives of neurology.

Disease amelioration with tocilizumab in a treatment-resistant patient with neuromyelitis optica: implication for cellular immune responses.

H. Hartung, G. Antoch, B. Turowski, 2013, JAMA neurology.

Blockade of signaling via the very late antigen (VLA-4) and its counterligand vascular cell adhesion molecule-1 (VCAM-1) causes increased T cell apoptosis in experimental autoimmune neuritis

R. Gold, G. Stoll, K. Toyka, 2002, Acta Neuropathologica.

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia

H. Hartung, T. Olsson, B. Kieseier, 2014, Neurology.

Infectious risk stratification in multiple sclerosis patients receiving immunotherapy

H. Hartung, H. Wiendl, S. Meuth, 2017, Annals of clinical and translational neurology.

Symptomatic therapy in multiple sclerosis: the role of cannabinoids in treating spasticity

H. Hartung, B. Kieseier, C. Warnke, 2012, Therapeutic advances in neurological disorders.

Superficial siderosis of the central nervous system: pathogenetic heterogeneity and therapeutic approaches

D. Brechtelsbauer, U. Sliwka, P. Flachenecker, 2003, Acta neurologica Scandinavica.

Multiple Sclerosis Therapy Consensus Group (MSTCG): position statement on disease-modifying therapies for multiple sclerosis (white paper)

J. Lünemann, A. Gass, C. Enzinger, 2021, Therapeutic advances in neurological disorders.

Cladribine as a therapeutic option in multiple sclerosis.

H. Hartung, B. Kieseier, C. Warnke, 2012, Clinical immunology.

Currently Approved Disease-Modifying Drugs

B. Kieseier, C. Warnke, V. Leussink, 2016 .

Thymic Epithelium Determines a Spontaneous Chronic Neuritis in Icam1tm1JcgrNOD Mice

H. Hartung, M. Roden, L. Steinman, 2014, The Journal of Immunology.

Interferon β bei Multipler Sklerose

H. Hartung, B. Kieseier, V. Leussink, 2010, Der Nervenarzt.

Immunomodulatory treatment strategies in multiple sclerosis

H. Wiendl, B. Kieseier, O. Stüve, 2008, Journal of Neurology.

Sudden deafness from stroke

M. Naumann, K. Reiners, V. Leussink, 2005, Neurology.

Relapse-independent multiple sclerosis progression under natalizumab

H. Hartung, S. Meuth, P. Albrecht, 2021, Brain communications.

Multiple sclerosis therapy consensus group (MSTCG): answers to the discussion questions

J. Lünemann, A. Gass, C. Enzinger, 2021, Neurological Research and Practice.

Multiple Sklerose Therapie Konsensus Gruppe (MSTKG): Positionspapier zur verlaufsmodifizierenden Therapie der Multiplen Sklerose 2021 (White Paper)

Zoë R. Hunter, J. Lünemann, A. Gass, 2021, Der Nervenarzt.

Restoring Axonal Function with 4-Aminopyridine: Clinical Efficacy in Multiple Sclerosis and Beyond

X. Montalban, H. Hartung, V. Leussink, 2018, CNS Drugs.

Safety and efficacy of dimethyl fumarate in multiple sclerosis: a multi-center observational study

H. Hartung, R. Gold, R. Hoepner, 2016, Journal of Neurology.

[Interferon β for multiple sclerosis. How much is good enough?].

H. Hartung, B. Kieseier, C. Warnke, 2010, Der Nervenarzt.

4-Aminopyridin (Fampridin)

H. Hartung, B. Kieseier, V. Leussink, 2010, Der Nervenarzt.

Escalating immunotherapy of multiple sclerosis--new aspects and practical application.

K. Hess, A. Gass, L. Kappos, 2004, Journal of neurology.

Vestibular hypofunction after monosodium glutamate ingestion: broadening the spectrum of ‘Chinese restaurant syndrome’

H. Hartung, B. Kieseier, O. Stüve, 2016, Journal of Neurology.

Cladribine impedes in vitro migration of mononuclear cells: a possible implication for treating multiple sclerosis

B. Kieseier, V. Leussink, T. Dehmel, 2009, European journal of neurology.

Initial lymphocyte count and low BMI may affect fingolimod-induced lymphopenia

H. Hartung, T. Olsson, B. Kieseier, 2014, Neurology.

Monomethylfumarate reduces in vitro migration of mononuclear cells

H. Hartung, H. Wiendl, B. Kieseier, 2014, Neurological Sciences.

Thymic Epithelium Determines a Spontaneous Chronic Neuritis in Icam1tm1JcgrNOD Mice

H. Hartung, M. Roden, L. Steinman, 2014, The Journal of Immunology.